论文部分内容阅读
随着经济的发展及人们生活方式的改变,糖尿病的患病率逐年上升,目前我国总体糖尿病患病率9.7%~([1])。双胍类、磺脲类、噻唑烷二酮类和α糖苷酶抑制剂为传统的口服降糖药~([2])。新型口服降糖药二肽基肽酶-Ⅳ(DPP-Ⅳ)抑制剂的降糖机制与传统药物有所不同,其以葡萄糖浓度依赖性通过减少肠促胰素的降解针对α、β细胞进行双向调节,临床疗效确切,现就DPP—Ⅳ抑制剂的研究进展予以综述。
With the economic development and people’s lifestyle changes, the prevalence of diabetes increased year by year, at present, the overall prevalence of diabetes in China 9.7% ~ ([1]). Biguanides, sulfonylureas, thiazolidinediones and alpha glucosidase inhibitors are the traditional oral antidiabetic drugs ~ ([2]). The hypoglycemic mechanism of the new oral hypoglycemic agent, dipeptidyl peptidase-IV (DPP-IV) inhibitor, differs from traditional drugs in that it acts on alpha and beta cells in a glucose concentration-dependent manner by reducing the degradation of incretin. Two-way adjustment, the exact clinical efficacy, the research progress of DPP-Ⅳ inhibitors are reviewed.